Logo

Diversa and Medarex Agree to Co-Develop Antibodies

Oct 17, 2003

NEW YORK, Oct. 17 (GenomeWeb News) - San Diego-based Diversa and Princeton, NJ-based Medarex yesterday announced they have entered into an R&D collaboration to develop and optimize antibodies to be used as drug targets.

 

Diversa plans to use its DirectEvolution technology, which generates randomized protein variants, to help engineer monoclonal antibodies. Medarex will bring its experience developing human monoclonal antibodies and its "extensive collaborative network" to the deal, Diversa president and CEO Jay Short said in a statement.

 

Breaking News
The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.